Oropharyngeal Dysphagia clinical trials at University of California Health
4 research studies open to eligible people
Utilization of Negative Pressure Suction to Reduce Aspiration in Oropharyngeal Dysphagia
“An ear nose and throat study for people with stomach tubes”
open to eligible people ages 18 years and up
This is an investigator initiated prospective study to determine whether the use of a negative pressure suction in the hypopharynx will reduce the amount of aspiration during Video Fluoroscopic Swallowing Exam (VFSE) among patients with oropharyngeal dysphagia.
at UC Davis
Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia
open to eligible people ages 18 years and up
The primary objective of this study is to evaluate the safety of Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) during the 12 months following treatment of tongue dysphagia in male and female patients who have undergone surgery and/or chemo- and/or radiotherapy for squamous cell cancer of the oropharynx.
at UC Davis
Autologous Muscle Derived Cells for Treatment of Tongue Dysphagia
“Contribute to discoveries that may improve healthcare for you, your family, and your community by volunteering for research!”
open to eligible people ages 18 years and up
The primary objective of this double-blind, randomized, placebo-controlled, multicenter clinical trial is to evaluate the safety of AMDC-GIR during the 24 months following 2 consecutive treatments of tongue dysphagia in male and female patients who have undergone surgery and/or chemo- and/or radiotherapy for squamous cell cancer of the oropharynx.
at UC Davis UCSF
QUantitative Assessment of Swallowing After Radiation (QUASAR)
open to eligible people ages 18 years and up
To use novel methods for quantitative analysis of VFSS (videofluoroscopic swallow study, also known as modified barium swallow) to study and compare dysphagia in patients treated for head and neck carcinoma with concurrent radiation therapy and chemotherapy (cisplatin) or targeted therapy (cetuximab) vs. immunotherapy (pembrolizumab, nivolumab, or durvalumab). Our hypothesis is that pharyngeal constriction will be greater (lower ratio) with concurrent immunotherapy compared to chemotherapy, as measured by the pharyngeal constriction ratio (PCR).
at UCSD
Our lead scientists for Oropharyngeal Dysphagia research studies include Loren K Mell, MD Maggie Kuhn, MD Peter Belafsky, MD, PhD.
Last updated: